Hill, Andrew M.; Gebo, Kelly; Hemmett, Lindsay; … - In: PharmacoEconomics 28 (2010) S1, pp. 169-181
counts, during the first year of therapy in highly treatment-experienced, HIV-infected adults in different healthcare … mean annual per-patient cost of DRV/r-based treatment was 2-19% higher than that of control PI-based therapy during the …-based HAART may lower non-antiretroviral-related costs compared with control PI-based therapy in highly treatment-experienced, HIV …